Literature DB >> 8848188

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b.

A S Dayal1, M A Jensen, A Lledo, B G Arnason.   

Abstract

Fifteen percent of multiple sclerosis patients about to be treated with interferon beta-1b exhibited elevated numbers of circulating interferon-gamma-secreting cells, defined as a value that exceeded the mean value for healthy controls by more than two standard deviations. Sixty percent of patients receiving the drug exhibited elevated interferon-gamma-secreting cell numbers during their first 2 months of treatment. Values normalized after 3 months. Prednisone treatment during the first month on the drug prevented the interferon-gamma-secreting cell surge.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8848188     DOI: 10.1212/wnl.45.12.2173

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

3.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.

Authors:  P Sarchielli; O Presciutti; R Tarducci; G Gobbi; A Alberti; G P Pelliccioli; A Orlacchio; V Gallai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

4.  Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients.

Authors:  An-Guor Wang; Yen-Ching Lin; Shuu-Jiun Wang; Ching-Piao Tsai; May-Yung Yen
Journal:  Jpn J Ophthalmol       Date:  2006-12-18       Impact factor: 2.447

5.  Flow cytometric analysis of in vitro proinflammatory cytokine secretion in peripheral blood from multiple sclerosis patients.

Authors:  L T Nguyen; M Ramanathan; F Munschauer; C Brownscheidle; S Krantz; M Umhauer; C Miller; E DeNardin; L D Jacobs
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.317

Review 6.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

7.  Prescribing recommendations for interferon-Beta in multiple sclerosis.

Authors:  B Weinstock-Guttman; R A Rudick
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

8.  Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.

Authors:  Chulbul M Ahmed; Ezra N Noon-Song; Kaisa Kemppainen; Massimo P Pascalli; Howard M Johnson
Journal:  J Neuroimmunol       Date:  2012-10-27       Impact factor: 3.478

9.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

Review 10.  Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS.

Authors:  Ulrich Kalinke; Marco Prinz
Journal:  Immunol Cell Biol       Date:  2012-03-20       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.